作者: Daniela Topolar , Barbara Götz , Stefan Schönberger , Dagmar Dilloo , Claudia Papewalis
DOI: 10.1007/10_2012_158
关键词:
摘要: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment option in disorders, immunodeficiencies and leukemia. To date graft-versus-host disease (GvHD) represents life-threatening complication even if associated with beneficial antileukemic reactivity. GvHD the clinical manifestation of donor cells reacting against host tissue. Because their ability to facilitate endogenous repair attenuate inflammation, MSC have evolved as highly attractive cellular therapeutic allo-HSCT. Here we report on experience use enhance engraftment prevent treat acute chronic GvHD. In early trials, shown considerable benefit setting manifest These encouraging results warrant further exploration.